Table 3.

Unadjusted and adjusted associations between IDH definitions and mortality on the basis of logistic regression models

DefinitionHEMO Cohort (n=1409)aLDO Cohort (n=10,392)a
(+) IDHb(−) IDHUnadjusted OR (95% CI) (+) IDH versus (−) IDHAdjusted ORc (95% CI) (+) IDH versus (−) IDH(+) IDHb(−) IDHUnadjusted OR (95% CI) (+) IDH versus (−) IDHAdjusted ORd (95% CI) (+) IDH versus (−) IDH
Nadir90n=167n=12422.26e1.56fn=1054n=93382.10e1.30f
Died: 79 (47.3%)Died: 353 (28.4%)(1.63 to 3.14)(1.05 to 2.31)Died: 218 (20.7%)Died: 1035 (11.1%)(1.78 to 2.47)(1.07 to 1.57)
Nadir100n=390n=10191.97e1.22n=2841n=75511.75e1.13
Died: 162 (41.5%)Died: 270 (26.5%)(1.54 to 2.52)(0.90 to 2.31)Died: 475 (16.7%)Died: 778 (10.3%)(1.54 to 1.98)(0.97 to 1.31)
Fall20n=1288n=1210.960.76n=9271n=11210.65e0.84
Died: 394 (30.6%)Died: 38 (31.4%)(0.64 to 1.44)(0.47 to 1.24)Died: 1066 (11.5%)Died: 187 (16.7%)(0.55 to 0.77)(0.69 to 1.02)
Fall30n=1049n=3601.060.94n=7428n=29640.78e0.99
Died: 325 (31.0%)Died: 107 (29.7%)(0.82 to 1.38)(0.68 to 1.31)Died: 837 (11.3%)Died: 416 (14.0%)(0.69 to 0.88)(0.86 to 1.15)
Fall20Nadir90n=151n=12581.95e1.32n=898n=94941.83e1.20
Died: 67 (44.4%)Died: 365 (29.0%)(1.38 to 2.75)(0.88 to 1.97)Died: 171 (19.0%)Died: 1082 (11.4%)(1.53 to 2.19)(0.98 to 1.47)
Fall30Nadir90n=131n=12781.85f1.27n=740n=96521.52e1.15
Died: 57 (43.5%)Died: 375 (29.3%)(1.29 to 2.67)(0.83 to 1.95)Died: 124 (16.8%)Died: 1129 (11.7%)(1.24 to 1.86)(0.92 to 1.43)
KDOQIn=118n=12910.951.04
Died: 35 (29.7%)Died: 397 (30.8%)(0.63 to 1.43)(0.65 to 1.66)
HEMOn=353n=10561.46f1.01
Died: 130 (36.8%)Died: 302 (28.6%)(1.13 to 1.88)(0.75 to 1.37)
Nadir90+Sxgn=6n=14031.130.34
Died: 2 (33.3%)Died: 430 (30.7%)(0.21 to 6.20)(0.06 to 2.04)
Nadir90+Intgn=100n=13091.95f1.39
Died: 45 (45.0%)Died: 387 (29.6%)(1.29 to 2.94)(0.86 to 2.23)
  • a Outcome for the HEMO cohort is 2-year mortality, and outcome for the LDO cohort is 1-year mortality.

  • b IDH defined as ≥30% of exposure period HD sessions meeting the specified definition.

  • c Multivariate logistic models were adjusted for age (per 10 years), sex, race (black or nonblack), ICED (≤1, 2, or 3), smoking status (current smoker or nonsmoker), diabetes, heart failure, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, vintage (≤0.9, 1–1.9, 2–3.9, or ≥4 years or missing), access (graft, fistula, or catheter), postdialysis weight (quartiles; kilograms), delivered treatment time (minutes), albumin (≤2.9, 3–3.9, or ≥4 g/dl or missing), hematocrit (percentage), UF volume (liters), predialysis SBP (≤129, 130–159, or ≥160 mmHg), residual renal function (≤200 or >200 ml/d), hospitalization during exposure period (yes or no), Kt/V group (high or low), flux group (high or low), center, and use of α-adrenergic blocker, renin-angiotensin system blocker, β-blocker, calcium channel blocker, nitrates, or other antihypertensives.

  • d Multivariate logistic models were adjusted for age (per 10 years), sex, race (black, nonblack, or missing), diabetes, heart failure, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, vintage (≤0.9, 1–1.9, 2–3.9, or ≥4 years or missing), access (graft, fistula, or catheter), postdialysis weight (quartiles; kilograms), delivered treatment time (minutes), albumin (≤2.9, 3–3.9, or ≥4 g/dl or missing), hemoglobin (grams per deciliter), UF volume (liters), predialysis SBP (millimeters Hg), equilibrated Kt/V (<1.2, ≥1.2, or missing), missed sessions during exposure period (0, 1, 2, or ≥3), and use of α-adrenergic blocker, renin-angiotensin system blocker, β-blocker, calcium channel blocker, nitrates, and other antihypertensives.

  • e P value<0.001.

  • f P value<0.05.

  • g Given the small n meeting the IDH definition in ≥30% of HD sessions, definition tertiles were examined; point estimates were similar (data not shown).